Academic Journal
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis
| العنوان: | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis |
|---|---|
| المؤلفون: | TOSI, FEDERICA MARIA, E. Magni, A. Amatu, G. Mauri, K. Bencardino, M. Truini, S. Veronese, L. De Carlis, G. Ferrari, M. Nichelatti, A. Sartore-Bianchi, S. Siena |
| المساهمون: | F. Tosi, E. Magni, A. Amatu, G. Mauri, K. Bencardino, M. Truini, S. Veronese, L. De Carli, G. Ferrari, M. Nichelatti, A. Sartore-Bianchi, S. Siena |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2017 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | BRAF, Colorectal cancer biomarker, Colorectal cancer prognosi, KRAS, Liver metastases, Settore MED/06 - Oncologia Medica |
| الوصف: | Treatment of metastatic colorectal cancer includes resection of liver metastases, however, no biomarkers drive selection of patients. We performed a meta-analysis including 1833 patients treated with complete liver resection, showing that Kirsten rat sarcoma viral oncogene homolog and b-viral oncogene homolog B1 mutations are negatively associated with survival. This supports integration of mutational status into a combined score to better identify candidates for resection of colorectal cancer liver metastases. Background The purpose of the study was to evaluate whether the mutational status of Kirsten rat sarcoma viral oncogene homolog (KRAS) or b-viral oncogene homolog B1 (BRAF) could be an independent prognostic factor in the subset of patients with colorectal cancer liver metastases (CRLM) who undergo complete liver resection. Materials and Methods A systematic literature review was performed to identify articles reporting relapse-free survival (RFS) and/or overall survival (OS) of patients who underwent complete liver resection for CRLM, stratified according to KRAS and BRAF mutational status. Hazard ratios (HRs) from multivariate analyses were pooled in the meta-analysis. Results Eleven studies, including 1833 patients, were eligible for the meta-analysis. Nine of them reported OS stratified according to KRAS mutation. The pooled analysis revealed that KRAS mutation was negatively associated with OS (HR, 1.674; 95% confidence interval [CI], 1.341-2.089; P < .001). Nine among 11 studies reported RFS stratified according to KRAS mutation and HRs in multivariate analysis were available in 7. In a pooled analysis, KRAS mutation was negatively associated with RFS (HR, 1.529; 95% CI, 1.287-1.817; P < .001). In 3 studies HRs of the multivariate analysis regarding the OS according to BRAF mutational status were also available, showing a negative association with OS (HR, 3.055; 95% CI, 1.794-5.204; P < .001). Conclusion KRAS mutations are negatively associated with OS and RFS in patients who undergo ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/28216246; info:eu-repo/semantics/altIdentifier/wos/WOS:000408269300004; volume:16; issue:3; firstpage:e153; lastpage:e163; numberofpages:11; journal:CLINICAL COLORECTAL CANCER; http://hdl.handle.net/2434/552341; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85012875416 |
| DOI: | 10.1016/j.clcc.2017.01.004 |
| الاتاحة: | http://hdl.handle.net/2434/552341 https://doi.org/10.1016/j.clcc.2017.01.004 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.36BB38FF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.clcc.2017.01.004 |
|---|